AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04743921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reparel Knee Sleeve
Description: Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
Study NCT06185621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg aspirin
Description: Patients received oral 100mg aspirin, one tablet daily for 2 years
Study NCT05856916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
Study NCT05856916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (in the form of lactose) will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
Study NCT06039462 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Application of a virtual reality headset
Description: Use of a headset to experience a different reality
Study NCT05015192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH102
Description: tablets, orally
Study NCT05015192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets, orally
Study NCT06015139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cotton roll-coated viscoelastic polymer pads
Description: relton-hall frame cotton roll-coated viscoelastic polymer pads
Study NCT06015139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: viscoelastic polymer pads
Description: relton-hall frame viscoelastic polymer pads
Study NCT06491108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil 5 Mg Oral Tablet
Description: Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
Study NCT06491108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 Mg Oral Tablet
Description: Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
Study NCT02043821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 14days
Study NCT02043821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: 14 days
Study NCT05060653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBRT followed by surgical stabilization within 24-48 hours
Description: In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
Study NCT06350838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.
Study NCT05217485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zio 14-day cardiac patch
Description: A wearble adhesive cardiac patch (14-day) called Zio
Study NCT04918030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-hospital staged PCI
Description: After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
Study NCT04918030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Out-hospital staged PCI
Description: During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
Study NCT05149222 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital ACT
Description: This is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia.
Study NCT04605302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCC/MCC-T
Description: Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract
Study NCT04605302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard gastroscopy
Description: Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
Study NCT04857996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX1325
Description: Patients will be administered a single 50 μL UBX1325 IVT injection
Study NCT04857996 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham procedure
Study NCT06037733 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CTV omitted or delineated
Description: Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
Study NCT06037733 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CTV omitted or delineated
Description: Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
Study NCT05796102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment
Study NCT04226690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active CBD/THC Dose 1
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
Study NCT04226690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active CBD/THC Dose 2
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
Study NCT04226690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo comparator
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
Study NCT05261763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: abc
Study NCT05261763 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needing
Description: xyz
Study NCT04885088 — intervention group
Intervention type: DEVICE
Intervention: Wisdom bracelet
Description: Wisdom bracelet
Study NCT05897723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Radiofrequency
Description: Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
Study NCT04788251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based fall prevention intervention (Modified Otago Exercise Programme and Modified Stepping On Programme)
Description: The modified OEP is a group exercise programme that consists of progressive strength and balance exercises led by trained exercise leaders (fitness instructors or health coaches). The supervised sessions will be conducted twice a week (1 hour each) for 7 weeks. Participants will be given an exercise booklet and encouraged to exercise at home.~The modified SOP is a group fall prevention programme that consists of exercise sessions and discussions on various falls prevention aspects facilitated by a trained programme leader and supported by programme facilitators and peer facilitators. The supervised sessions will be conducted once a week (2 hours each) for 7 weeks. Participants will be given homework and encouraged to exercise at home. In addition, there will be an optional home visit (Week 11), a 1-hour booster session (Week 19) and a telephone call (Week 31).
Study NCT04788251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: To receive fall prevention resources while waiting for their programme to start
Study NCT05651165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacoactive balloon angioplasty. Lutonix®
Description: Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
Study NCT05651165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mimetic stent.Supera®
Description: Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
Study NCT05316402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training on the risks associated with sun exposure
Description: 15-minute power point and presentation on the risks of sun exposure
Study NCT05316402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dosimetry
Description: dosimetry
Study NCT06331442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Patients allocated to the first group (n=10) will receive photodynamic therapy. Buccal/labial surface around the bracket of each tooth in the upper dental arch (from right to left second premolar) will be treated with toluidine blue based dye (155 mg/mL; LaserHF Paro-PDT, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany). This photosensitive solution will be applied on teeth with the sterile syringe and left for 60 s. Then, the excess of the photosensitive solution will be rinsed with the sterile syringe containing a saline solution. Then, a 660 nm diode laser (Laser HF, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany) will be used for photoactivation (power output 100 mW, power density 124.34 W/cm2 and continuous working mode). Buccal/labial surface of each tooth will be radiated for 60 s at approximately 5 mm away from the enamel surface. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
Study NCT06331442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tricalcium phosphate (TCP) varnish with 5% NaF
Description: Tricalcium phosphate varnish with 5% NaF (Clinpro™ White Varnish, 3M ESPE 3M Deutschland GmbH, Germany) will be applied to the patients allocated to the second group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
Study NCT06331442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine varnish
Description: Chlorhexidine varnish (1% CHX, 1% thymol; Cervitec® Plus, Ivoclar Vivadent AG, Schaan, Liechtenstein) will be applied to the patients allocated to the third group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
Study NCT05642455 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel
Description: Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \<40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
Study NCT06143865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed system aspiration
Description: Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
Study NCT04898062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRP-apheresis
Description: The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
Study NCT05896631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7.5 mg hyperbaric bupivacaine
Description: Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
Study NCT05896631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg hyperbaric bupivacaine
Description: Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
Study NCT06308874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amg dose administration group
Description: Orally, Amg tablet single administration
Study NCT06308874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amg dose administration group- Placebo
Description: Orally, Placebo Amg tablet single administration
Study NCT06308874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bmg dose administration group
Description: Orally, Bmg tablet single administration
Study NCT06308874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bmg dose administration group- Placebo
Description: Orally, Placebo Bmg tablet single administration
Study NCT05183867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: HMP is a 4-week mobile health (mHealth) meditation training program.
Study NCT05183867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Minds Program
Description: HMP is a 4-week mobile health (mHealth) meditation training program.
Study NCT04448535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gingko Biloba
Description: oral intake of Gingko Biloba, 240mg/day for 4 weeks
Study NCT05468229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzagliatin
Description: single oral dose of dorzagliatin 50 mg
Study NCT05468229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT06365723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green Walk
Description: All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Green' urban environment.
Study NCT06365723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gray Walk
Description: All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Gray' urban environment.
Study NCT05412732 — intervention group
Intervention type: OTHER
Intervention: prospective biomedical research study
Description: A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).
Study NCT05262699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile stimulation
Description: Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
Study NCT05262699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Devices mounted, no stimulation
Study NCT05092919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flavor
Description: Sweet flavored vs. non-flavored cigarillos.
Study NCT06466031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI & PET fusion
Description: MRI+T1C in fusion with MET-PET will be used for tumor resection and/or radiotherapy planning. Resection will be terminated after removal of PET-assigned tumor margin or in case any neuromonitoring-based indications regarding neurological damage occur.
Study NCT06466031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI+T1C
Description: MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.
Study NCT06466031 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MRI+T1C
Description: MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.
Study NCT06098365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: segmental cervical stabilization exercises
Description: Segmental spine stabilization exercises were composed of axial extension, cervical extension exercises, cervico-scapulothoracic strengthening and cranio-cervical flexion exercises.
Study NCT06098365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cervical isometric exercises
Description: Cervical isometric exercises consist of 6 sets in a sitting position, each movement lasting 10 seconds, each repeated 5 times, with a 5-second rest in between.
Study NCT05905120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludivenlafaxine hydrochloride sustained-release tablets
Description: 80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
Study NCT05961995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heartfulness meditation
Description: Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart.
Study NCT05040724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: ivermectin placebo
Study NCT05040724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin
Description: ivermectin placebo
Study NCT04804514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH001
Description: The study drug is applied to teeth
Study NCT04804514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is applied to teeth
Study NCT05843851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: Test for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
Study NCT05666336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.
Study NCT05666336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
Study NCT05666336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.